The primary prevention of coronary heart disease in women: An overview

Cardiology Review

Volumn 22, Issue 3 SPEC. ISS., 2005, Pages 14-22

  Hong, Susan ^a   Friedman, Jordana ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY RISK; DIABETES MELLITUS; EXERCISE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; OBESITY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION;

EID: 20044377595     PISSN: 10926607     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Prescott E, Osler M, Andersen PK, et al. Mortality in women and men in relation to smoking. Int J Epidemiol. 1998;27(1):27-32.
2. Mosca L, Appel LJ, Benjamin EJ, et al; AHA. Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol. 2004;24(3):e29-e50.
3. Wegner N. The natural history of coronary artery disease in women. In: Charney P, ed. Coronary Artery Disease in Women: What All Physicians Need to Know. Philadelphia, Pa: American College of Physicians; 1999:3-35.
4. King KB, Quinn JR, Delehanty JM, et al. Perception of risk for coronary heart disease in women undergoing coronary angiography. Heart Lung. 2002;31(4):246-252.
5. Perlman JA, Wolf PH, Ray R, et al. Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women. Am J Obstet Gynecol. 1988;158(6 pt 2):1568-1574.
6. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med. 1995;155(1):57-61.
7. Brezinka V, Padmos I. Coronary heart disease risk factors in women. Eur Heart J. 1994;15(11):1571-1584.
8. Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002;16(3):329-355.
9. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol 1989;130(4):646-654.
10. Nanchahal K, Ashton WD, Wood DA. Association between blood pressure, the treatment of hypertension, and cardiovascular risk factors in women. J Hypertens. 2000;18(7):833-841.
11. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291-1297.
12. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal woman: a clinical approach. Curr Hypertens Rep. 2002;4(6):464-470.
13. Rich-Edwards JW, Manson JE, Hennekens CH, et al. The primary prevention of coronary heart disease in women. N Engl J Med. 1995;332(26):1758-1766.
14. Hypertension Detection and Follow-up Program Cooperative Group. Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1988;259(14):2113-2122.
15. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338 (8778):1281-1285.
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
17. Allen JK, Blumenthal RS. Coronary risk factors in woman six months after coronary artery bypass grafting. Am J Cardiol. 1995;75(16):1092-1095.
18. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension. 2000;36(5):780-789.
19. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21(8):1258-1265.
20. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study [published correction appears in JAMA. 1991;265(24):3249]. JAMA. 1991;265(5):627-631.
21. Barrett-Connor E, Giardina EG, Gitt AK, et al. Women and heart disease: the role of diabetes and hyperglycemia. Arch Intern Med. 2004;164(9):934-942.
22. Hu G; DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia. 2003;46(5):608-617.
23. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham study [published correction appears in JAMA. 1989;261(13):1884]. JAMA. 1988;260(23):3456-3460.
24. Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival. The Minnesota Heart Survey. Diabetes Care. 1991;14(7):537-543.
25. Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141(6):413-420.
26. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27(suppl 1):S15-S35.
27. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257(16):2176-2180.
28. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA. 1986;256(20):2835-2838.
29. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham study. Ann Epidemiol 1992;2(1-2):23-28.
30. Brunner D, Weisbort J, Meshulam N, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol. 1987;59(15):1271-1276.
31. Wilson PW, Evans JC. Coronary artery disease prediction. Am J Hypertens. 1993;6(11 pt 2):309S-313S.
32. Bass KM, Newschaffer CJ, Klag MJ, et al. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 1993;153(19):2209-2216.
33. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol. 2002;90(8A):77i-84i.
34. Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2(1-2):161-176.
35. Jacobs DR Jr, Mebane IL, Bangdiwala SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol. 1990;131(1):32-47.
36. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham study. Am Heart J. 1987;114(2):413-419.
37. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274(7):539-544.
38. Walsh JME. Lipids. In: Charney P, ed. Coronary Artery Disease in Women: What AH Physicians Need to Know. Philadelphia: American College of Physicians; 1999:101-128.
39. Stensvold I, Tverdal A, Urdal P, et al. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993;307 (6915):1318-1322.
40. Pedersen TR, Kjekshus J, Berg K, et al; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl. 2004;5(3):81-87.
41. Lewis SJ, Sacks EM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32 (1):140-146.
42. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
43. Shepherd J, Cobbe SM, Ford I, et al; West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl. 2004;5(3):91-97.
44. Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005-2016.
45. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
46. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
47. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679-1687.
48. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
49. Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women. Lancet. 1972;2 (7782):835-838.
50. Frantz ID Jr, Dawson EA, Ashman PL, et al. Test of effect of lipid lowering by diet on cardiovascular risk. The Minnesota Coronary Survey. Arteriosclerosis. 1989;9 (1):129-135.
51. Mann JI, Doll R, Thorogood M, et al. Risk factors for myocardial infarction in young women. Br J Prev Soc Med. 1976;30 (2):94-100.
52. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317(21):1303-1309.
53. Nyboe J, Jensen G, Appleyard M, et al. Smoking and the risk of first acute myocardial infarction. Am Heart J. 1991;122(2):438-447.
54. Njolstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark study. Circulation. 1996;93(3):450-456.
55. Ciruzzi MA, Schargrosky H, Pramparo P, et al. [Advanced age and risk factors for acute myocardial infarction]. Medicina (B Aires). 2002;62(6):535-543.
56. Barbash GI, White HD, Modan M, et al. Acute myocardial infarction in the young-the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J. 1995;16(3):313-316.
57. Cavender JB, Rogers WJ, Fisher LD, et al. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. J Am Coll Cardiol. 1992;20(2):287-294.
58. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med. 1990;322(4):213-217.
59. Hennekens CH. Risk factors for coronary heart disease in women. Cardiol Clin. 1998;16(1):1-8.
60. Royce JM, Corbett K, Sorensen G, et al. Gender, social pressure, and smoking cessations: the Community Intervention Trial for Smoking Cessation (COMMIT) at baseline. Soc Sci Med. 1997;44(3):359-370.
61. Baldini EH, Strauss GM. Women and lung cancer: waiting to exhale. Chest. 1997;112(4 suppl):229S-234S.
62. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999;99(9):1165-1172.
63. Bjorntorp P. Regional patterns of fat distribution. Ann Mem Med. 1985;103(6 pt 2):994-995.
64. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med. 1995;333(11):677-685.
65. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995;122(7):481-486.
66. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968-977.
67. Kushi LH, Fee RM, Folsom AR, et al. Physical activity and mortality in post-menopausal women. JAMA. 1997;277 (16):1287-1292.
68. Sesso HD, Paffenbarger RS, Ha T, et al. Physical activity and cardiovascular disease risk in middle-aged and older women. Am J Epidemiol. 1999;150(4):408-416.
69. Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: is "no pain, no gain" passe? JAMA. 2001;285(11):1447-1454.
70. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347(10):716-725.
71. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J (Clin Res Ed). 1988;296(6618):320-331.
72. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2(8607):349-360.
73. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266(4):521-527.
74. Hammond EC, Garfinkel L. Aspirin and coronary heart disease: findings of a prospective study. Br Med J. 1975;2(5965):269-271.
75. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299 (6710):1247-1250.
76. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762.
77. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens. 2000;18(5):629-642.
78. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice [published correction appears in Lancet. 2001;357(9262):1134]. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357(9250):89-95.
79. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001;85(3):265-271.
80. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161-172.
81. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med. 2002;346(19):1468-1474.
82. Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med. 2000;9(1):19-27.
83. Trends in aging-United States and worldwide. MMWR Morbid Mortal Wkly Rep. 2003;52(6):101-104, 106.